Clinical Trials on Beta-thalassemia Major in Russian Federation

Total 71 results

Federal Research Institute of Pediatric Hematology...

Unknown

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Anesthesia | Pediatric Cancer | Beta-Thalassemia | Hepatic Metastases | Pediatric Tumor | Pediatric Hepatoblastoma

Russian Federation
AstraZeneca

Completed

Observational Prospective Study OPTIMA II - Follow-up (OPTIMAII)

Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Russian Federation
Center for Vascular Pathology, Moscow

Enrolling by invitation

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

Spinal Tumor | Spinal Hemangioma | Beta Blocker Toxicity

Russian Federation
Sanofi

Completed

An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients (FIDELIO)

Major Depressive Disorder

Romania, Russian Federation, Ukraine, Mexico, Slovakia, Chile, South Africa
Novartis Pharmaceuticals

Completed

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Myelodysplastic Syndrome | Thalassemia

Russian Federation
H. Lundbeck A/S

Completed

Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder

Major Depressive Disorder

Austria, Russian Federation
National Medical Research Center for Rehabilitation...
Pirogov Russian National Research Medical University; DNKOM LLC; The Orenburg...

Recruiting

Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old

Cardiovascular Diseases | Nervous System Diseases | Urologic Diseases | Diabetes | Neuromuscular Diseases | Hypercholesterolemia | Gout | Hyperbilirubinemia | Hyper IgE Syndrome | Hyper-LDL-cholesterolemia | Hyper Beta Lipoproteinemia | Hyper Eosinophilic Syndrome

Russian Federation
Sanofi

Completed

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder (LENA)

Depressive Disorder

Canada, Russian Federation, Bulgaria, Mexico, Argentina, Chile, Croatia
Sanofi

Completed

Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder

Major Depressive Disorders

Russian Federation, Spain, Singapore, Taiwan, Tunisia, Argentina, Chile, Hong Kong, Morocco, South Africa, Greece
Sanofi

Completed

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Depressive Disorder

United States, France, Russian Federation, Sweden, Turkey, Czech Republic, Mexico, Croatia
AstraZeneca

Completed

Retrospective Observational Study DIANA Study (DIANA)

Major Depressive Episode

Russian Federation
GlaxoSmithKline

Completed

Safety and Efficacy Study in Patients With Major Depressive Disorder

Depressive Disorder

Russian Federation
Sanofi

Completed

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder (CALYPSO)

Depressive Disorder | Major Depression

France, Poland, Romania, Russian Federation, Bulgaria, Serbia, Slovakia, Czech Republic, Mexico, Argentina, Croatia, Finland, South Africa
GlaxoSmithKline

Terminated

A Study of GW856553X For the Treatment of Depression

Depressive Disorder, Major

India, Russian Federation, Estonia
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.

Depressive Disorder, Major

Russian Federation, Estonia
Sanofi

Completed

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder (COMPASS)

Depressive Disorder, Major

United States, Russian Federation, Germany, Estonia, Mexico, Korea, Republic of, Chile, South Africa
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study of Patients With Major Depressive Disorder and Residual Apathy

Major Depressive Disorder

Mexico, Russian Federation, Australia, Taiwan, Canada
Janssen Research & Development, LLC

Completed

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Major Depressive Disorder

Ukraine, Bulgaria, Romania, Russian Federation, Hungary, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study of JNJ-61393215 in the Treatment of Depression

Major Depressive Disorder With Anxious Distress

United States, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression

Major Depressive Disorder

France, Italy, Russian Federation, South Africa
GlaxoSmithKline

Completed

Major Depressive Disorder In The Elderly

Depressive Disorder, Major

Belgium, Australia, Russian Federation, Netherlands, Norway, Finland
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Sunovion

Completed

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose (RESOLVE 1)

Major Depressive Disorder With Mixed Features

United States, Serbia, Ukraine, Russian Federation, United Kingdom
Pfizer

Terminated

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

Depressive Disorder, Major

United States, Former Serbia and Montenegro, Russian Federation
Pfizer

Completed

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Chile, United States, Estonia, Russian Federation
Sanofi

Completed

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder (AGATE)

Major Depression

Belgium, Canada, Chile, Estonia, Finland, France, Germany, Netherlands, Russian Federation, Slovakia, South Africa, Sweden
Janssen Research & Development, LLC

Completed

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Depressive Disorder | Anxiety

Ukraine, United Kingdom, Spain, United States, Russian Federation, Moldova, Republic of
GlaxoSmithKline

Completed

Clinical Study to Test a New Drug to Treat Major Depression (PKI113009)

Depressive Disorder, Major

Bulgaria, United States, Germany, Russian Federation, Estonia
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Bipolar Depression | Major Depressive Disorder

United States, Bulgaria, Russian Federation, Serbia, Ukraine
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Slovakia, Poland, Hungary, Japan, Russian Federation
AstraZeneca

Completed

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Major Depressive Disorder

Russian Federation, United States, Estonia, Ukraine, Finland, Argentina
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
Genzyme, a Sanofi Company

Completed

A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

Gaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic Form

United States, Israel, Mexico, Russian Federation, Argentina, Italy
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
Eli Lilly and Company

Completed

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
Takeda
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

France, Ukraine, Germany, Malaysia, South Africa, Korea, Republic of, Russian Federation, Czech Republic, Lithuania, United Kingdom, Latvia, Australia, Netherlands, Poland, Taiwan
Eli Lilly and Company

Completed

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Russian Federation, South Africa, France, Ukraine, Slovakia
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Major Depressive Disorder

Finland, Sweden, Estonia, Bulgaria, United States, Canada, Germany, Korea, Republic of, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Ukraine, United Kingdom
H. Lundbeck A/S

Completed

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression (VIVRE)

Major Depressive Disorder

Spain, Czechia, Slovakia, Estonia, Sweden, Argentina, Belgium, Bulgaria, Latvia, Mexico, Russian Federation, Ukraine
Eli Lilly and Company

Completed

A Study in Prevention of Re-emergence of Depression Symptoms

Major Depressive Disorder

United States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Finland, Germany, Romania, Russian Federation, Serbia, Ukraine
Hoffmann-La Roche

Completed

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Major Depressive Disorder

United States, Germany, Austria, Russian Federation, Ukraine, Canada, Slovakia, South Africa
Eli Lilly and Company
Boehringer Ingelheim

Completed

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Depressive Disorder, Major

United States, France, Germany, Italy, Russian Federation, Sweden
Sunovion

Completed

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Insomnia | Major Depressive Disorder

France, Poland, Russian Federation, United Kingdom, Austria, Hungary, Croatia, Romania, Serbia, Ukraine
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
Eli Lilly and Company

Completed

A Study in Adult Patients With Major Depressive Disorder

Depressive Disorder, Major

United States, Finland, Poland, Russian Federation, Argentina

Clinical Trials on Beta-thalassemia Major in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations